AstraZeneca PLC (AZN)vsNexgel Inc (NXGL)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
NXGL
Nexgel Inc
$0.29
+0.34%
HEALTHCARE · Cap: $3.09M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 508444% more annual revenue ($61.37B vs $12.07M). AZN leads profitability with a 17.0% profit margin vs -51.3%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
NXGL
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+43.8%
Fair Value
$2.49
Current Price
$0.29
$2.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Revenue surging 27.8% year-over-year
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -80.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : NXGL
The strongest argument for NXGL centers on Price/Book, Revenue Growth. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : NXGL
The primary concerns for NXGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.51 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while NXGL is a growth play — different risk/reward profiles.
NXGL carries more volatility with a beta of 0.75 — expect wider price swings.
NXGL is growing revenue faster at 27.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 39/100), backed by strong 17.0% margins. NXGL offers better value entry with a 43.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Nexgel Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?